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Most patients with metastatic carcinomas have no hope for cure by
standard forms of cancer therapy such as surgery, radiation and
chemotherapy. A promising treatment strategy for many types of
cancer is immunotherapy. The goal of this kind of therapy is to
stimulate the immune system to recognize and kill cancer cells
by modifying tumour cells or modifying the host response.
Indeed, autologous immunological effector cells have been used
successfully to treat patients with advanced stage malignancies
(Rosenberg et al, 1986, 1990).
We reported a protocol generating large numbers of efficient cyto-
toxic effector cells termed CIK cells (Mehta et al, 1995; Schmidt-
Wolf et al, 1991, 1994). Cytokine-induced killer (CIK) cells are
non-major histocompatibility complex-restricted cytotoxic lympho-
cytes generated by incubation of peripheral blood lymphocytes
with anti-CD3 monoclonal antibody, interleukin (IL)-2, IL-1 and
interferon gamma (IFN-g). CIK cells represent cells with high
anti-tumour cytotoxicity in vitro and in vivo (Schmidt-Wolf et al,
1991). CIK cells possess enhanced cytotoxic activity as compared to
standard lymphokine activated killer (LAK) cells (Lu et al, 1994;
Margolin et al, 1997). The higher anti-tumour activity of CIK cells is
mainly due to the higher proliferation rate of CD3 and CD56 double
positive cells (Schmidt-Wolf et al, 1994). Because of the increase in
cytotoxicity and high proliferative response, CIK cells have a 73-fold
increase in total lytic units per culture as compared to IL-2-stimulated
LAK cells. In a tumour colony assay these cells were capable of
generating a log cell kill of 2.5–3.5 (Schmidt-Wolf et al, 1991). This
represents an additional increase of about two logs of tumour cell kill
as compared to LAK cells. As shown previously, the increase in cyto-
toxic activity has little toxic effect on a progenitor class of normal
human bone marrow cells, since colony-forming unit granulocyte–
macrophage (CFU-GM) activity of human bone marrow cells was
only partially impaired (75% of control; Schmidt-Wolf et al, 1991).
Furthermore, it has been shown that CIK cells are capable of eradi-
cating an established tumour in a severe combined immune deficient
(SCID) mouse human lymphoma model (Lu et al, 1994).
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Summary Natural killer-like T lymphocytes termed cytokine-induced killer (CIK) cells have been shown to eradicate established tumours in a
severe combined immune deficient (SCID) mouse/human lymphoma model. Recently, we demonstrated that CIK cells transfected with
cytokine genes possess an improved proliferation rate and a significantly higher cytotoxic activity as compared to non-transfected cells. Here,
in a phase I clinical protocol, autologous CIK cells were generated from peripheral blood obtained by leukapheresis in patients with metastatic
renal cell carcinoma, colorectal carcinoma and lymphoma. CIK cells were transfected with a plasmid containing the interleukin-2 (IL-2) gene
via electroporation. Transfected cells generated IL-2 in the range of 330–1800 pg 10–6 cells 24 h–1 with a mean of 836 pg 10–6 cells 24 h–1. Ten
patients received 1–5 intravenous infusions of IL-2-transfected CIK cells; five infusions with transfected CIK cells were given. In addition, the
same patients received five infusions with untransfected CIK cells for control reasons. In three patients, WHO grade 2 fever was observed.
Based on polymerase chain reaction of peripheral blood transfected cells could be detected for up to 2 weeks after infusion. There was a
significant increase in serum levels of interferon gamma (IFN-g), granulocyte–macrophage colony-stimulating factor (GM-CSF) and
transforming growth factor beta (TGF-b) during treatment. Interestingly, there was also an increase in CD3+ lymphocytes in the blood of
patients during therapy. In accordance, a partial increase in cytotoxic activity in peripheral blood lymphocytes (PBLs) was documented when
patient samples before and after therapy were compared. Concerning clinical outcome, six patients remained in progressive disease, three
patients showed no change by treatment, and one patient with lymphoma developed a complete response. In conclusion, we were able to
demonstrate that CIK cells transfected with the IL-2 gene can be administered without major side-effects and are promising for future
therapeutic trials. © 1999 Cancer Research Campaign
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depend on exogenous addition of cytokines like IL-2, IL-7 or IL-
12 for proliferation (Csipai et al, 1996; Zoll et al, 1998). The
cytokines control the expansion of antigen-specific cells and influ-
ence the activity of cells within the immune system (Hickman et
al, 1990). CIK lymphocytes transfected with a cytokine expression
plasmid have shown improved cell proliferation and cytotoxic
activity (Finke et al, 1998).
In this clinical phase I trial (Schmidt-Wolf et al, 1994) we
generated autologous CIK cells, transfected CIK cells with the 
IL-2 gene and re-infused the cells into patients with metastatic
colorectal carcinoma, renal cell carcinoma and lymphoma.
MATERIALS AND METHODS
Patient accrual
Details of the protocol have been described (Schmidt-Wolf et al,
1994). In brief, eligibility criteria consisted of patients with
metastatic colon carcinoma, renal cancer, melanoma and
lymphoma, age between 18 and 70 years, Karnofsky score of
70–100. Exclusion criteria included time interval from chemo-
therapy and cytokine treatment less than 28 days, creatinine higher
than 265 mmol l–1, bilirubin above 51 mmol l–1, decompensated
heart insufficiency, ventricular rhythm disorders, severe psychi-
atric disease, active hepatitis A, B, or C, HIV. Patients were treated
as inpatients. Patients were informed of the investigational nature
of this study and written consent in accordance with institutional
policies was obtained before start of treatment. Approval of our
local ethics committee was obtained.
Generation of CIK cells
CIK cells were generated as described previously. In brief, non-
adherent Ficoll separated human peripheral blood mononuclear
cells were prepared and grown in RPMI-1640 medium (Gibco-
BRL, Berlin, Germany), consisting of 10% fetal calf serum
(FCS), FDA approved, (PAA, Cölbe, Germany), 25 mM HEPES,
100 U ml–1 penicillin and 100 U ml–1 streptomycin (Gibco-BRL,
Germany). A total of 1000 U ml–1 IFN-g (Dr Rentschler, Laupheim,
Germany) were added on day 0. After 24 h of incubation, 50 ng ml–1
of an antibody against CD3 (Orthoclone OKT 3, Cilag GmbH,
Sulzbach, Germany) and 100 U ml–1 IL-2 (EuroCetus GmbH,
Ratingen, Germany) were added. Cells were incubated at 37°C in a
humidified atmosphere of 5% carbon dioxide and subcultured every
3rd day in fresh complete medium and IL-2 at 3 ´ 106 cells ml–1.
CELL LINES
For HLA-matched cytotoxicity assays various cell lines were used
in this study. For patients with colorectal carcinoma we used HT
29 and CR 75 cells, for the patient with renal cell carcinoma we
used A 704 cells, and for lymphoma patients we used LAM 53
cells. To monitor NK-activity of the patients we used K562 cells
as targets in this assay. We received all cell lines from ATCC
(Rockville, MD, USA), except CR 75, which was grown in our
laboratory. The renal carcinoma cell line was grown in essential
modified Eagle’s medium (EMEM) with non-essential amino
acids (Gibco-BRL), sodium pyruvate, 10% FCS (Gibco-BRL),
100 U ml–1 penicillin and 100 U ml–1 streptomycin. K562, HT 29,
CR75 and LAM 53 cells were grown in RPMI-1640 (Gibco-BRL)
with 10% FCS, 100 U ml–1 penicillin and 100 U ml–1 strepto-
mycin.
Expression plasmid for IL-2
The plasmid pCEP-IL-2 was constructed on the basis of the
commercially available pCEP4 vector (Stratagene, NV Leek, The
Netherlands). It contains a cytomegalovirus (CMV)-promoter-
enhancer sequence, the cDNA from human IL-2 mRNA, a self-
replication-origin (EBNA-1 and OriP), a gene for ampicillin- and
for hygromycin-resistance and a SV-40 poly-adenosine (poly-A)
signal sequence. The gene for episomal replication is under control
of an Epstein–Barr virus (EBV) promoter and contains an EBV
poly (A) signal sequence (Finke et al, 1998).
Transfection of CIK cells
CIK cells were transfected via electroporation using the electro-
poration system easyject plus from Eurogentec, Seraing, Belgium.
One ´ 107 CIK-cells were suspended in 500 ml complete RPMI
medium and were mixed with 30 mg pCEP-IL-2-plasmid. This
mixture was transferred to a 4 mm electroporation cuvette and
pulsed with a double pulse programme. Parameters for the first
pulse were 650 V, 25 mF and 99 Ohm, for the second pulse 100 V,
1050 mF and 99 Ohm. After the pulse cells were transferred to
complete RPMI medium at a density of 3 ´ 106 cells per ml,
chloroquin at a final concentration of 100 mM was added to the cell
suspension. Cells were incubated in a humidified atmosphere at
37°C overnight, then counted and dead cells were separated from
the living cells by Ficoll separation before infusion.
Transfection efficiency was determined as described before
(Finke et al, 1998). In brief, b-galactosidase assays were carried
out 24 h after transfection of cells with an expression vector for
bacterial b-galactosidase. The vector was constructed on the basis
of the pCEP4 vector. Transfected cells were incubated with 5-
bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal; Sigma,
Deisenhofen, Germany) for 16–20 h at 37°C. Following incuba-
tion, aliquots were taken and the blue cells counted in a Neubauer
chamber. Colourless cells were also counted and the percentage of
transfected cells was calculated from the ratio between transfected
and non-transfected cells.
RNA extraction, reverse transcription and polymerase
chain reaction
RNA was extracted from CIK cells and from PBLs using the RNeasy
total RNA Kit (Qiagen, Hilden, Germany). RNA was reverse tran-
scribed (RT) into cDNA using a standard procedure with random
primers. No DNAase treatment was performed to remove residual
plasmid DNA. Polymerase chain reaction (PCR) was performed
using primers specific for IL-2 transcripts (Stratagene, Heidelberg,
Germany). Twenty-five cycles of amplification were performed.
Samples containing b-actin-specific primers (Stratagene) were used
to monitor integrity and amount of cDNA – human b-actin-
primers: TGACGGGGTC ACCCACACTG TGCCCATCTA,
CTAGAAGCAT TTGCGGTGGA CGATGGAGGG; human IL-2
primers: GATTGTGATA TTGAAGGTAA AGATGGC, CTTC-
CTTTAA CCTGGCCAGT GC.
Products of the PCR were analysed on a 3% agarose gel and
photographed after ethidium bromide staining.
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Most assays were performed using frozen cells. Therefore, cells
taken at different time points could be tested in one assay. For flow
cytometric analysis fresh cells were used.
Immunofluorescence and flow cytometry studies
Peripheral blood lymphocytes and CIK cells were stained using
various monoclonal antibodies against human surface antigens.
Antibodies used included antibodies against human CD3, CD4,
CD8, CD16, CD19, CD25, CD28, CD56, LFA-1, ICAM-1 and
HLA-DR (Immunotech Hamburg, Germany). Isotype-matched
antibodies were used as controls. Stained cells were washed and
subsequently analysed using a FACSCAN (Becton Dickinson).
Background staining using irrelevant antibodies was less than 2%.
A total of 104 cells were analysed for each sample.
Cytotoxicity assay
A Cyto Tox 96 non-radioactive cytotoxicity assay (Promega,
Madison, WI, USA) was used to compare the cytotoxic activity of
the transfected CIK cells with the non-transfected and to monitor
the cytotoxic activity of the PBLs during the treatment. It was
performed on days 1, 22, 25 and 43. This assay is a colourimetric
alternative to the 51Cr release assay. It quantitatively measures
lactate dehydrogenase (LDH), which is released upon cell lysis in
much the same way as 51Cr is released. Released LDH in culture
supernatants was measured in a 30-min incubation using a coupled
enzymatic assay. The amount of colour formed is proportional to
the number of lysed cells. Absorbance data were collected using a
96-well plate reader set to 490 nm. Five thousand target cells were
plated in triplicate sets in a V-bottom 96-well tissue culture plate
and incubated for 4 h with various ratios of effector to target cells.
After incubation, 50 ml aliquots from all wells were transferred to a
fresh 96-well plate. Fifty microlitres of the substrate mix was
added to each well of the plate and incubated at room temperature
for 30 min in the dark. Before measuring, 50 ml of a stop solution
was added to each well. K562, CR 75, HT 29, A-704 and LAM 53
cells were used as targets. Every experiment was performed in
triplicates and the mean value was calculated.
Proliferation assay
The proliferation assay ‘Easy for you’ (Biomedica, Vienna,
Austria) was performed to compare the proliferation of transfected
CIK cells with non-transfected cells and to determine the range of
stimulatory effects of a mitogen (phytohaemaglutinine) on PBLs.
Briefly, transfected and non-transfected cells were grown in 96-
well plates for 7 days, fed once after 3 days, analysed using a
chromophore substrate solution and read on a multiwell scanning
spectrophotometer (enzyme-linked immunosorbent assay (ELISA)
reader). Incubation with the substrate solution is 4 h, depending on
the metabolic capacity of the cells. The yellow tetrazolium
compound is converted to its red formazan derivative that has
its maximum of absorbance at 490 nm. A medium control is
subtracted in each well. Experiments were performed in triplicates
and the mean value was calculated.
ELISA
IL-2 levels in conditioned medium were determined by an
ELISA. The IL-2–ELISA kit was purchased from R&D Systems
(Quantikine, Minneapolis, MN, USA). It detects soluble IL-2
down to 30 pg ml–1 of IL-2. Briefly, microtitre plates were coated
with a monoclonal antibody specific for IL-2 and incubated to bind
IL-2 in cell culture supernatants. After several washes to remove
unbound proteins, an enzyme-linked (horseradish peroxidase)
polyclonal antibody was added that binds to the solid phase bound
IL-2. After washing, the substrate solution was added and devel-
oping colour was measured using a multiwell plate reader set to
450 nm. The optical density of the samples was compared to a
calibration curve. Standard samples according to WHO standards
from the suppliers were used to generate calibration curves.
Determination of cytokines other than IL-2
In addition to IL-2 in the supernatant of transfected cells we
determined the amount of IL-4, IL-12, granulocyte–macrophage
colony-stimulating factor (GM-CSF), IFN-g and tumour growth
factor beta (TGF-b) in the serum of the patients on day 0, 4, 22, 25
and 43. All cytokine levels were determined by an ELISA and all
kits were purchased from R&D systems, Quantikine. The assay
procedures were analogous to the procedure described above.
Delayed-type hypersensitivity
A commercially available recall-DTH test (Multi Test Merieux,
Leimen, Germany) was administered before and after treatment.
A positive skin-test reaction was defined as > 5 mm diameter
induration after 48 h.
Clinical outcome
A partial response was defined as a decrease of all measurable
tumour manifestations of more than 50% for at least 4 weeks
without new manifestations of disease. Stable disease was defined
as no decrease of measurable tumour manifestations (WHO,
1979).
Statistical analysis
Wilcoxon matched pairs test was used to analyse for statistical
significance. A P-value < 0.05 was considered significant.
RESULTS
Clinical assessment of the course of disease and
adverse effects
We monitored ten patients over a period of 43 days and performed
various in vitro studies with PBLs isolated from patient’s blood
collected on day 0, 4, 22, 25 and 43. In addition, we analysed
patient’s serum for the presence of cytokines and tested the super-
natant of transfected cells for the presence of IL-2.
Patient characteristics
Ten patients were enrolled in our clinical protocol. Median age
was 49.2 years (range 40–61). Nine patients were male, one
female. Karnofsky score of all patients was 70 or above. Seven
patients had metastatic colorectal carcinoma, two patients
lymphoma, one patient renal cell carcinoma. Nine patients had
metastases in lymph nodes, seven patients in the lung, five in the
liver and two in other viscera.
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Patients received one to five intravenous infusions of IL-2-trans-
fected CIK cells and five infusions of untransfected CIK cells. The
first cycle of infusions was given in 1 week from days 1 to 5, the
second cycle was given from days 22 to 26. Patients were random-
ized into either receiving transfected or untransfected cells first.
Patients obtained a median of 35 ´ 108 CIK cells with a range of
2.2–125 ´ 108 (Table 1). Vitality was between 58.8 and 98.6% in
the first three patients, and between 78.6 and 97.8% in the next
seven patients. Vitality was determined by trypan blue stain.
Clinical toxicity of treatment
Three patients developed WHO grade 2 fever that resolved the
next day with or without the addition of antibiotics in all patients
(Table 1). Sterility controls of CIK cells and blood cultures were
negative at all times. No other adverse events were detected.
Patient evaluation
Patients were evaluated before, during and after treatment. All
parameters were scored for statistical significance. In summary,
patients showed a statistically significant anemia on day 25 of
therapy and on day 43 after therapy (P = 0.012 and 0.043 respec-
tively), an increase in thrombocyte counts on days 22 and 43 (P =
0.013 and 0.041 respectively), an increase in potassium on days 4
and 22 (P = 0.042 and 0.028 respectively), an increase in alkaline
phosphatase on day 43 (P = 0.012) and an increase in CRP on days
25 and 43 (P = 0.028 and 0.043 respectively) as compared to day 1
of therapy. There was no significant change in all other laboratory
parameters including creatinine, bilirubin and tumour markers
(data not shown).
EBV status
Seven patients showed a positive EBV VCA-IgG and EBNA
antigen before treatment. One of these patients showed an addi-
tional EBV VCA-IgM after treatment. One patient with negative
EBV status before treatment showed a positive EBV VCA-IgG
and EBNA antigen after therapy. One patient was not evaluable
with respect to EBV (data not shown).
DTH reactivity
Multitest Merieux was performed before and after treatment
(Table 1). An increase in the reactivity against bacterial antigens
was seen in three of ten patients.
Patient outcome
All ten patients were in progressive disease when entering our
protocol. With respect to our protocol, clinical outcome was based
mainly on comparison of CT scans before and after treatment. Six
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Table 1 Patient characteristics, number of CIK cells administered and DTH reactivity
Age Sex Diagnosis HLA type Total cells Cells administered Multitest- Merieux Fever
administered per cycle per cycle before therapy after therapy
61 M Colon A2. A 25(10) 29.4 ´ 108
cancer B 18, B50: 51.9 ´ 108 22.5 ´ 108 Negative 11 mm/2 +
(21). Cw6, Bw6
52 M Colon A1. A24(9), B8, 11.4 ´ 109
cancer B62(15), Cw3, 12.5 ´ 109 10.6 ´ 108 5 mm/l 6 mm/l +
Cw7. Bw6
40 M Colon A2. A24(9), B7 92.1 ´ 108 87.8 ´ 108
cancer B27. Bw4, Bw6, Cw2, Cw7 4.4 ´ 108 Negative Negative –
55 M Colon A1. A9. B7, B8, 21.5 ´ 108
cancer Bw6, Cw7 25.4 ´ 108 3.9 ´ 108 12 mm/l 7 mm/3 –
46 M Colon A2. A25(10), 5.5 ´ 107
cancer B18. B51(5), 21.9 ´ 107 16.4 ´ 107 Negative 2 mm/l +
Bw4. Bw6
53 M Colon A2. A28. B8(60). 8.4 ´ 108
cancer B62(15). Bw4, 14 ´ 108 5.6 ´ 108 Negative Negative –
Bw6. Cw3
54 F Colon A1. B7. B8 2.7 ´ 108
cancer Bw6. Cw7 6.8 ´ 108 4.1 ´ 108 Negative 2 mm/l –
41 M Follicular A2.A30.(19).B13 4.5 ´ 107
lymphoma B62(15).Bw4.Bw6 4.8 ´ 108 4.3 ´ 108 Negative Negative –
grade II Cw4.Cw6.DR7.
DR12(5).DR52. DR53
A1.A26(10).B27. 8.7 ´ 108
54 M Renal B57(17).Bw4. 9.2 ´ 108 5.0 ´ 107 5 mm/l ND –
cancer Cw1.Cw6
54 M Follicular A1.A33(19).B8. 4.5 ´ 108
lymphoma B14.Bw6.Cw7.Cw8 18.4 ´ 108 13.9 ´ 108 9 mm/2 7 mm/2 –
grade I DR3.DR10.Dr52
DR53
One cycle of CIK cell infusions consisted of five infusions on consecutive days followed by a second cycle of five infusions after 3 weeks. DTH reactivity was
performed on days 1 and 43 respectively. Results of Multitest Merieux are given as the sum of total diameter in mm/number of reactive agents before and after
therapy. Fever was temperature WHO grade 2. M, male, F, female. ND, not done.patients remained in progressive disease, three patients showed no
change by treatment. In one patient with follicular lymphoma
grade I, a pre-existing bone marrow involvement as the only sign
of disease resolved after CIK cell therapy. This was scored as a
complete clinical response.
In vitro immunological responsiveness
Determination of gene transcription using PCR
We looked for the presence of IL-2 transcripts in the blood of all
patients during treatment. Transcription of IL-2 cDNA was shown
using RT-PCR. Further, we looked for the presence of IL-2 cDNA
in transfected and non-transfected CIK cells (treatment cycles I
and II) of all patients. Non-transfected CIK cells were shown to
contain only small amounts of IL-2 mRNA in contrast to cells
transfected with the IL-2 vector, which showed successful trans-
fection in every case (data not shown). Based on PCR of peripheral
blood transfected cells could be detected for up to 2 weeks after
infusion. Concerning RNA of the PBL, one patient showed no IL-
2 mRNA, one patient showed a band only on day 25 of the treat-
ment and one patient showed a band on day 0, which disappeared
during the time of observation. In seven patients, IL-2 mRNA was
detectable on each evaluation day during treatment (data not
shown).
Cytokine production of CIK cells
Successfully transfected CIK cells produced a mean of 836 pg 10–6
cells 24 h–1 IL-2. The range between patients was 330–1800 pg
10–6 cells 24 h–1 as measured by ELISA (data not shown). The
percentage of actually transfected CIK cells varied between 5 and
15%. However, it was difficult to transfect CIK cells derived from
the two lymphoma patients. Here, we measured 75 and 0 pg 10–6
cells 24 h–1 IL-2 respectively. In non-transfected cells, IL-2 expres-
sion was below 30 pg ml–1. Also, when CIK cells were transfected
with vector constructs of identical basis but containing a b-galac-
tosidase gene, IL-2 production was below 30 pg.
Cytokine profile of the serum from patients
In addition to IL-2, we assayed the serum of the patients for IL-4,
IL-12, IFN-g, GM-CSF and TGF-b. In no case was a production of
IL-2, IL-4 or IL-12 detectable. None of the patients had detectable
amounts of IFN-g in serum on day 0, but in six patients IFN-g was
detectable during treatment. In patient 8 (P8) we found 67 pg ml–1
on day 43, the other patients showed varying amounts of IFN-g, in
particular on days 22, 25 and 43. Highest amounts were in the
range of 16–49 pg ml–1. This increase in single patients was statis-
tically significant, with a P-value of 0.0369 (Table 2).
In two patients we found 40 pg ml–1 GM-CSF in the serum on
day 0. In one patient, the amount of GM-CSF increased during
treatment to a maximum value of 184 pg ml–1 on day 43. In all
patients GM-CSF increased from 8.1 to 28.7 during treatment,
with a P-value of 0.0312 (Table 2). CIK cells expressed a mean of
700 pg ml–1 10–6 cells of GM-CSF.
We detected a high TGF-b level in the serum of all patients
(> 20 ng ml–1) with the exception of P4 (725 pg) and P5 (9 ng).
However, there was a significant increase in the expression of
TGF-b in all patients during treatment when we calculated day 0
versus day 25 or 43, with a P-value of 0.0171 and 0.0096 respec-
tively (Table 2).
Expression of surface antigens on PBLs during treatment
PBLs were stained with various monoclonal antibodies as outlined
above. There was a significant increase of CD3+CD8+ PBLs in
relative numbers from 20% to 25% (mean value) in all patients on
day 25 with a P-value of 0.0049 (Figure 1); however, the increase
in absolute numbers was not statistically significant. CD3+ and
CD4+ cells increased from 507±182 and 237±162 to 708±340 and
327±204 per pl blood on day 22 (P < 0.05 for CD3) respectively
(Table 3). In addition, there was an increase in CD25+ cells on day
25. Significance was not seen at any other time points.
Expression of surface antigens on CIK cells
Concerning the expression of surface molecules on transfected and
non-transfected CIK cells surface molecules remained unaltered.
However, there was a significant decrease in the expression of
CD3+CD56+ cells from 14 to 6% with a P-value of 0.0391, and of
LFA-1+ cells from 96% to 65% with a P-value of 0.0167 (data not
shown).
Proliferation of CIK cells
When transfected CIK cells were compared with non-transfected
cells (in vitro experiments), CIK cells transfected with the IL-2
gene showed an increased proliferation rate as compared to non-
transfected cells (0.371±0.148 versus 0.161±0.043). This
enhanced proliferation rate was statistically significant, but cells
proliferated less as compared to positive controls fed with exoge-
nous IL-2 (mean value 0.606±0.211). The P-value was 0.0415
when we calculated significance of CIK cells without transfection
versus transfected cells. These results correlate well with results
we obtained when transfecting CIK cells with IL-7 via receptor-
mediated gene transfer (Finke et al, 1998).
Cytotoxicity of PBLs collected during treatment
The cytotoxic effect of PBLs was monitored during the treatment
using various HLA-matched carcinoma cell lines as targets in a
non-radioactive cytotoxicity assay. Cytotoxic activity of PBLs
increased during treatment. This was true either against HLA-
matched carcinoma cell lines as well as against K562 cells. We
used effector to target cell ratios of 2, 5, 10, 20:1 cells. In every
case the cytotoxicity of the PBLs increased during the treatment as
compared to their activity before treatment. However, only at
single effector to target ratios was this increase statistically signifi-
cant. At the 20:1 effector to target cell ratio we found a mean
value of 22.5±26% cell killing for the PBL on day 0 and a mean
value of 35±21% on day 43, with a P-value of 0.029 against K562.
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Table 2 Cytokine production in the serum of the patients on day 0 and day
43
pg ml–1 on day 0 pg ml–1 on day P-value
(mean value) 43 (mean
value)
IL-2 0 0
IL-4 0 0
IL-12 0 0
IFN-gamma 0 13.7 0.0369
GM-CSF 8.1 28.7 0.0312
TGF-b 16.970 35.400 0.0096We found a statistically significant increase from 8.2±9.7% on day
0 to 13.2±9.6% on day 25, with a P-value of 0.016 at an effector to
target ratio of 10:1 against HLA-matched tumour cells. Figure 2A
shows the cytotoxic activity of the PBLs against K562, Figure 2B
against HLA-matched tumour cells.
Cytotoxicity of CIK cells
In CIK cells we found an increase in cytotoxic activity when
comparing transfected to non-transfected cells. This was true
when using HLA-matched tumour cells as targets and this increase
was statistically significant for the effector to target ratio of 5:1.
Cytotoxic activity was increased from 3.8% to 9.7% with a P-
value of 0.0331. When using K562 cells as targets the cytotoxic
activity remained unaltered (data not shown).
DISCUSSION
The ability of malignant cells to survive exposure to cytotoxic
agents is a major obstacle to cure in cancer patients.
Immunological effector cells such as LAK cells (Grimm et al,
1982; Lynch et al, 1990), TILs (Rosenberg et al, 1986) or NK-like
T-cells, termed cytokine-induced killer (CIK) cells (Mehta et al,
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Figure 1 Flow cytometry of PBL during treatment. PBLs were stained with various antibodies and analysed by flow cytometry as described in Material and
Methods. For example, cell surface expression of CD3 and CD8 was determined on day 0 (A) and day 25 (B). Cells stained with an irrelevant antibody were
used as negative control. Here, data from one representative patient are shown
Table 3 Flow cytometry studies
PBL day 0 PBL day 4 PBL day 22 PBL day 25 PBL day 43
CD4+CD3+ 237±162 247±149 327±204 205±136 270±183
CD4+ 237±162 247±149 327±204 205±136 270±183
CD3+ 507±182 458±202 708±340 479±179 529±215
CD3+CD8+ 203±91 167±79 272±272 214±222 183±75
CD3+ 487±212 449±132 721±258 402±247 486±226
CD8+ 314±162 247±114 395±272 291±205 291±107
CD3+CD19+ 10±10 9±17 14±13 26±25 11±10
CD3+ 487±202 458±140 531±381 402±247 475±226
CD19+ 132±70 106±70 109±68 120±119 140±97
CD3+CD56+ 41±30 18±17 41±40 51±34 32±43
CD3+ 497±192 441±144 694±231 410±196 496±205
CD56+ 152±111 167±79 163±136 120±59 162±107
CD16+CD56+ 41±40 53±44 54±40 60±51 76±86
CD16+ 101±91 88±70 136±149 128±145 129±118
CD56+ 101±81 70±61 136±136 103±42 119±107
HLA-DR+CD25+ 20±20 18±17 27±27 51±42 22±21
HLA-DR+ 183±101 123±79 231±149 222±119 248±129
CD25+ 61±50 53±44 68±40 111±102 65±53
LFA 1+ 730±233 617±211 776±449 590±273 820±194
ICAM 1+ 649±354 484±317 544±36 410±333 518±420
CD28+ 446±192 344±167 544±285 316±196 356±237
PBLs were stained on day 0, 4, 22, 25 and 43 with various antibodies and analysed by flow cytometry. A total of 104 cells were analysed for each sample and
background staining was usually less than 2%. Data are presented as mean cell number per pl blood of ten separate experiments.1995, Schmidt-Wolf et al, 1997), may be suitable to remove
residual tumour cells resistant to chemotherapy. Large numbers of
these cells are necessary for effective immunotherapy. However, in
some patients it is difficult to obtain sufficient effector cell
numbers since these cells grow poorly in vivo.
Clinical trials on the use of gene-transfected lymphocytes were
hampered by a poor efficiency of gene transfer in lymphocytes and
a down-regulation of cytokine expression by lymphocytes (Hwu
et al, 1993). The reason for this gene transfer resistance is not
completely understood. Possibly, apoptosis plays a role in this
gene transfer resistance of lymphocytes (Ebert et al, 1997).
Retrovirus-mediated gene transfer is currently the method of
choice for transfection of human T lymphocytes. Viral vectors,
however, require dividing target cells (except for DNA-viruses
such as adenoviruses) and may raise safety questions in human
gene therapy (Schmidt-Wolf et al, 1996). CD3 receptor-mediated
gene transfer is an efficient method for the transfection of CIK
cells and cell mortality is relatively low, compared to other non-
viral gene transfer methods (Buschle et al, 1995). However, it
remains difficult to transfect large amounts of cells with this
method. Electroporation is a fast and cost-effective method for
transfection of large amounts of cells, but transfection efficiency is
slightly lower compared to CD3 receptor-mediated gene transfer.
Here, we report on the results of the first trial using autologous
IL-2 modified CIK immunological effector cells for the treatment
of ten patients with metastatic disease. This pilot study demon-
strates the feasibility and the low amount of toxicity of such an
approach. Three patients developed fever, one patient developed
anaemia. Two of the patients with fever received high amounts of
non-vital cells. This may explain the fever in these patients that
was self-limiting. After removing most of the non-vital cells with a
second Ficoll gradient centrifugation, no fever was seen in the
remaining patients.
There was a statistically significant increase in TGF-b in the
serum of patients treated with CIK cells. Serum levels were not
different in patients receiving CIK cells secreting high doses of IL-2
as compared to cells secreting low amounts of IL-2. TGF-b has been
shown to inhibit the growth of renal cell lines (Ramp et al, 1997) and
other human tumours (Markowitz et al, 1996). TGF-b promotes the
growth and differentiation of dendritic cells (Riedl et al, 1997). On
the other hand, aberrant expression of TGF-bhas been proposed as a
growth factor for malignant diseases (Wright et al, 1996). Therefore,
the importance of the TGF-b increase is still unclear.
Interestingly, increased amounts of IFN-g were measured in the
serum of patients after treatment. There was no correlation
between IL-2 levels of the cells and serum levels of IFN-g. IFN-g
seems to be important for elevation of expression of MHC class II
molecules improving the sensitivity of tumour cells against
immunological effector cells. Similarly, GM-CSF has been
described as being important for elevation of expression of MHC
class II molecules. Interestingly, there was also a significant
increase in GM-CSF in the serum of patients during therapy. A
correlation existed in patient 10 between the serum cytokine level
concerning IFN-g and GM-CSF and clinical response. In patient 7
an increase of CD3+CD56+ lymphocytes was observed together
with an increase of IFN-g and GM-CSF in the serum.
There was a statistically significant increase in CD3+ T lympho-
cytes in the blood of patients during therapy. In accordance, there
was an increase in cytotoxic activity in PBL derived from the
patients that was partially significant. In three patients there was
an increase in the response against recall antigens (Multitest
MerieuxR) as compared to prior to vaccination. This may reflect an
increase in efficiency of the immune system.
Clinical outcome in three patients showing no change of disease
and one patient with complete response appears promising in
patients with progressive metastatic disease resistant to
chemotherapy. The patient with complete response only received
CIK cells with a low amount of IL-2, but still responded clinically.
In vivo, CIK cells have been shown to be effective in eradicating
established tumours in mice (Lu et al, 1994). These data show that
transfection is not absolutely necessary for effectiveness of CIK
cells. However, in vitro data support the concept that CIK cells
transfected with cytokine genes possess an augmented cytotoxic
activity as compared to untransfected cells (Finke et al, 1998).
To our knowledge, this is the first report of the clinical use of
CIK cells and of IL-2-transfected CIK cells. Further studies are
necessary to evaluate the efficacy of such a treatment in particular
in patients with limited disease.
Immunological effector cells expressing IL-2 1015
British Journal of Cancer (1999) 81(6), 1009–1016 © 1999 Cancer Research Campaign
T0
T22
T25
T43
40
30
20
10
0
0 2:1 5:1 10:1 20:1
Effector cells: target cells
C
y
t
o
t
o
x
i
c
i
t
y
 
(
%
)
A
T0
T22
T25
T43
40
30
20
10
0
0 2:1 5:1 10:1 20:1
Effector cells: target cells
C
y
t
o
t
o
x
i
c
i
t
y
 
(
%
)
B
Figure 2 Cytotoxicity of PBL during treatment. Cytotoxicity of PBL was examined using a non-radioactive cytotoxicity test. The figures show the lysis of two
different target cells by PBLs on day 0, 22, 25 and 43. Target cells include K562, a CML cell line (A) and HLA-matched tumour cells (B). All experiments were
performed in triplicates. Both figures represent data from ten experimentsACKNOWLEDGEMENTS
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